{
  "docId": "019de072-ae97-77c9-95d7-9575c5bb6949",
  "docSlug": "921d262ee9ef21bcd4aec91f3f72a4c5",
  "documentTitle": "Certara | Investor Presentation Deck | 30 slides",
  "authorId": "certara",
  "authorName": "Certara",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 30,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "traction",
  "function": "show_traction",
  "density": "balanced",
  "nDataPoints": 90,
  "notes": "The slide uses a table to categorize drugs by therapeutic area (Oncology, Rare Disease, CNS, Infectious Disease, Gastroenterology, Cardiovascular, Other).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-ae97-77c9-95d7-9575c5bb6949/8",
  "deckHref": "/decks/019de072-ae97-77c9-95d7-9575c5bb6949",
  "deckJsonHref": "/decks/019de072-ae97-77c9-95d7-9575c5bb6949.json",
  "deckAnchorHref": "/decks/019de072-ae97-77c9-95d7-9575c5bb6949#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "callout",
      "text": "We believe that our customers would have faced millions in additional costs and significant launch delays had they conducted human clinical trials for these drug label claims",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2013d9a6-d644-43e3-b6a4-d3363582110b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.75,
        "w": 0.88,
        "x": 0.11,
        "y": 0.13
      },
      "kind": "table",
      "text": "Table of 90 drugs categorized by therapeutic area (Oncology, Rare Disease, CNS, Infectious Disease, Gastroenterology, Cardiovascular, Other) with company and drug names.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d2933404-d90a-4895-b33a-8dc6da9e47bc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Simcyp software has informed 250+ labels for 90 novel drug approvals",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d46fa55a-b007-4d3d-b66c-95ff7e5c79b8",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 8,
      "from": 8,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "07ef4ca2-e78d-4825-8a05-46a5ad7b07bf",
      "evidence": "The deck presents a slide on the costs of not using biosimulation",
      "position": 0,
      "objective": "Highlight the benefits of using biosimulation",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}